# A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

> **NCT07671339** · PHASE1 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 20 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** ELI-002 7P
- **DRUG:** Tislelizumab
- **DRUG:** mFOLFIRINOX

## Key facts

- **NCT ID:** NCT07671339
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-22
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-06-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07671339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07671339, "A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT07671339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*